BioVie EBIT

The latest EBIT for BIVI is $-20M as of March 2026. That compares with $-19M in the prior-year period — down 6.0% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside BioVie's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIVI's EBIT moved from $-19M to $-20M — a 6.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioVie's operating scale or balance-sheet position.

Against Healthcare companies, BIVI currently prints $-20M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at BioVie's growth, margins, and balance sheet.

A EBIT figure of $-20M for BIVI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting BIVI's EBIT ($-20M), review year-over-year change from $-19M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.